保列治治疗合并慢性前列腺炎的良性前列腺增生症疗效观察

Clinical effects of finasteride on benign prostatic hyperplasia associated with chronic prostatitis

目的 观察保列治治疗合并慢性前列腺炎的良性前列腺增生症的临床疗效。方法 选择经临床确诊的合并慢性前列腺炎的良性前列腺增生症患者40例,口服保列治5 mg,1次/d,共3个月,分别于治疗前,治疗3个月后行国际前列腺症状评分(IPSS)、尿流率、残余尿量、前列腺体积及前列腺液常规等指标测定。结果 用药3个月后IPSS平均降低31.6％,最大尿流率平均升高38.3％,残余尿量平均减少38.6％。前列腺体积平均缩小18.1％。前列腺液白细胞计数平均减少39.8％。前列腺液检查好转率50％。前列腺体积≥40 mL组及<40 mL组的前列腺液检查好转率分别为66.7％及31.6％,两者比较P<0.05。结论 保列治治疗合并慢性前列腺炎的良性前列腺增生症,对慢性前列腺炎及良性前列腺增生症均效果良好。对慢性前列腺炎伴前列腺体积较大者效果尤佳。

Objective To investigate the clinical effects of finasteride on benign prostatic hyperplasia (BPH) associated with chronic prostatitis(CP). Methods 40 cases of BPH associated with CP were selected. Finasteride was administered orally with the recommended dose of 5 mg, once daily for 3 months. IPSS, urine flow rate, residual urine volume, prostate volume and expressed prostatic secretion(EPS) were measured before and 3 months after administration respectively. Results Three months after administration, on an average, IPSS decreased by 31.6%, maximal urine flow rate increased by 38.3%, residual urine volume reduced by 38.6%,prostate volume reduced by 18.1%, EPS leukocyte count reduced by 39.8%. The effective rate of EPS was 50%. The effective rate of EPS in prostate volume≥40 mL group was 66.7%, while<40 mL group was 31.6 %, there were significant differences between two groups(P<0.05). Conclusions Finasteride is effective for the treatment of BPH associated with CP.